Exemestane
Brand Names: Aromasin
Methodology & AI Transparency ⓘ
Exemestane Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Exemestane tablets are an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ).
- 2 Real-world patient consensus: Zero-PHI community consensus: 84% favorable across 16 logged regimens (Aromasin).
- 3 Typical cash cost range: 30-day cash pricing ranges from $11.90 on Cost Plus Drugs to $34.50 walk-in retail (NADAC $0.5751/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Exemestane: headache (13%), fatigue (16%), insomnia (12%).
Ask our AI Specialists anything about Exemestane
Exemestane Mechanism, CYP450 Pathways & DailyMed Monograph
Exemestane tablets are an aromatase inhibitor indicated for: adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane tablets for completion of a total of five consecutive years of adjuvant hormonal therapy ( 14.1 ). treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy ( 14.2 ).
12.1 Mechanism of Action Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) by the aromatase enzyme in peripheral tissues.
Systemic exposure to Exemestane reflects Oral fraction absorbed ranges from 76% to 88% (Exemestane 25) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of exemestane, sustaining receptor engagement across a 24 hours terminal elimination (Exemestane SPL) half-life window (oral tmax achieved within 2 to 3 hours following exemestane ingestion response profile).
Dosing protocols (25 mg/1 Tablet, Film Coated or 25 mg/1 Tablet or 25 mg/1 Tablet, Sugar Coated or 25mg Tablet) balance efficacy (84.00% patient satisfaction across 16 logs) against fatigue (16% of reports), headache (13% of reports), insomnia (12% of reports), with strict avoidance in exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.; patients with a known hypersensitivity to the drug or to any of the excipients ( 4 )..
Rifampin or anticonvulsant inducers can diminish Exemestane systemic exposure and clinical response.
Reconcile eGFR-adjusted medications before escalating Exemestane in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.
- Patients with a known hypersensitivity to the drug or to any of the excipients ( 4 ).
Logged Side-Effect Incidence (16 Reports)
Exemestane Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Exemestane)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)? Combining molecular and clinico-pathologic factors enhances prognostic information. Breast (Edinburgh, Scotland) • 2025-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 40633461 ↗ |
| Can This Approach Help? Inside the Latest Research on Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in LY75 and GPR160 participate in epithelial-to-mesenchymal transition and growth pathways, in both cases with SNP-dependent variation in regulation. Clinical pharmacology and therapeutics • 2021-10-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34048027 ↗ |
Exemestane Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.5751/unit (~$17.25/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $11.90 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $13.68 / mo | View logs ↓ |
Exemestane Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Exemestane RxNorm Concept ID | 310261 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5751 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $11.90 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 84.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Exemestane Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Exemestane integrating DailyMed SPL (2024-05-29), CMS NADAC ($0.5751/unit), and 16 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Exemestane community threads and patient logs by age, biological sex, dosage, and treatment duration.